JAMA Psychiatry, published by the American Medical Association, stands as a leading peer-reviewed journal in the fields of psychiatry and mental health, featuring an impressive impact factor that reflects its significance in advancing research and clinical practice. With an ISSN of 2168-622X and an E-ISSN of 2168-6238, this journal operates on a comprehensive access model that allows for the dissemination of vital research findings to a global audience. Since its inception in 2013, JAMA Psychiatry has consistently ranked in the top quartile (Q1) in both the Medicine (miscellaneous) and Psychiatry and Mental Health categories, with a remarkable Scopus rank of #4 out of 567, placing it in the 99th percentile. Addressed from its headquarters in Chicago, Illinois, the journal's objectives encompass the publication of original clinical research, innovative treatment strategies, and insightful reviews that enrich the understanding of psychiatric disorders. By bridging the gap between research and real-world application, JAMA Psychiatry remains an essential resource for researchers, clinicians, and students dedicated to improving mental health outcomes.

Archives of Neuroscience is a multidisciplinary journal dedicated to advancing the field of neuroscience through the publication of original research articles, review papers, and case studies. Published by BRIEFLAND, this journal aims to bridge the gap between neuroscience research and clinical applications, fostering a deeper understanding of brain function, neurological disorders, and potential therapeutic approaches. With an ISSN of 2322-3944 and an E-ISSN of 2322-5769, Archives of Neuroscience serves as an essential platform for researchers, professionals, and students alike, encouraging open access to knowledge and insights that drive innovation in the field. Although coverage was discontinued in Scopus from 2016 to 2017, the journal continues to uphold rigorous standards of academic excellence, making it a valuable resource for the neuroscience community seeking to explore and disseminate new findings. The journal is committed to providing timely access to research tools and findings that are crucial for informed decision-making in both academic and clinical settings.

Psychiatry International, published by MDPI, is a dynamic and open-access journal dedicated to advancing the field of psychiatry and mental health. Since its inception in 2020, this journal has emerged as a vital platform for the dissemination of innovative research and impactful insights across various subdisciplines, encompassing psychiatric nursing, general medicine, and neuroscience. With an E-ISSN of 2673-5318, Psychiatry International facilitates accessibility to research findings and fosters collaboration among researchers, healthcare professionals, and academics worldwide. The journal's alignment with modern Open Access principles reflects its commitment to enhancing the visibility and reach of psychiatric research. Despite being relatively new, it has demonstrated a promising standing in Scopus rankings, positioning itself within the top quartile for Nursing (Psychiatric Mental Health) and showing potential for growth in other related categories. By encouraging submissions that address the latest developments and challenges in mental health, Psychiatry International aims to catalyze progress in mental health awareness and intervention strategies, making it an essential resource for anyone engaged in the field.

Brain Imaging and Behavior is a premier journal published by SPRINGER, dedicated to advancing the understanding of the relationship between brain function and behavior through innovative imaging techniques. Since its inception in 2007, the journal has provided a crucial platform for researchers and professionals in fields such as Behavioral Neuroscience, Cognitive Neuroscience, and Psychiatry and Mental Health. With an impressive ranking within the Q1 category in Radiology, Nuclear Medicine and Imaging and maintaining strong Q2 status in several other categories, the journal is positioned as a leading resource for groundbreaking research. The journal aims to disseminate high-quality studies that explore neurobiological underpinnings of behavior, utilizing cutting-edge imaging technologies. Although it is not an open-access journal, the visibility and impact of published works in Brain Imaging and Behavior continue to influence the scientific community significantly, underscoring the critical intersection between imaging science and neuroscience.

CORTEX is a premier international journal published by Elsevier Masson, focusing on the cutting-edge areas of cognitive neuroscience, psychology, and neurology. With an impressive impact factor that places it in Q1 quartiles across multiple categories such as Cognitive Neuroscience and Neuropsychology, this journal serves as a vital resource for researchers, clinicians, and students alike. Established in 1964, CORTEX has continued to excel in disseminating high-quality scholarly work, offering insights that significantly enhance our understanding of the brain's functioning and behavior. Although not an open-access publication, it provides various access options to ensure the dissemination of knowledge is as wide-reaching as possible. As the field of cognitive psychology evolves, CORTEX remains at the forefront, fostering an environment for interdisciplinary collaboration and innovation. Researchers seeking to stay engaged with the latest advancements will find CORTEX an indispensable tool for their professional development.

MOLECULAR PSYCHIATRY, published by SpringerNature, is a premier peer-reviewed journal that has established itself as a leading platform for the dissemination of cutting-edge research in the fields of neuroscience, molecular biology, and psychiatry. With an impressive impact factor and a reputation for excellence, the journal is ranked Q1 in key categories, signifying its high academic quality and relevance. The journal’s scope spans groundbreaking studies and innovative therapeutic approaches that intersect at the molecular and cellular levels, providing invaluable insights into the biological underpinnings of psychiatric disorders. Since its inception in 1996, MOLECULAR PSYCHIATRY has evolved to support both established and emerging researchers, fostering a collaborative environment that enhances the understanding of mental health. It is committed to improving access to scientific knowledge, although it currently does not offer open access options. With its headquarters in London, the journal continues to play a pivotal role in enhancing the global dialogue on psychiatric and neurological advancements, making it an essential resource for academics and professionals dedicated to advancing mental health sciences.

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

The INTERNATIONAL JOURNAL OF NEUROSCIENCE, published by TAYLOR & FRANCIS LTD, stands as a vital resource in the field of neuroscience since its inception. With a proud history of publication from 1970 to 2024, this journal is committed to advancing knowledge in various domains of neuroscience, from fundamental research to clinical applications. It is indexed with an ISSN of 0020-7454 and an E-ISSN of 1563-5279, reflecting its wide reach and recognition. The journal maintains a respectable position in the academic landscape, categorized as Q2 in Medicine (miscellaneous) and Q3 in Neuroscience (miscellaneous) as of 2023, signifying its relevance among researchers and professionals. Although it currently does not offer open access, the journal remains a significant platform for disseminating groundbreaking research, thereby fostering collaboration and innovation within the neuroscience community. Located in the United Kingdom, the journal aims to bridge gaps in neuroscience knowledge, making it an essential reading for students, professionals, and researchers dedicated to unraveling the complexities of the nervous system.

PSYCHIATRIC GENETICS, published by LIPPINCOTT WILLIAMS & WILKINS, is a pivotal journal dedicated to the interdisciplinary study of genetic factors in psychiatric disorders, bridging the fields of genetics, psychiatry, and neuroscience. With a commitment to advancing research from its inception in 1990 and continuing through 2024, the journal provides a platform for innovative studies and findings that explore the genetic underpinnings of mental health. Although not currently an Open Access publication, it reaches a wide audience concerned with the complex interplay between genetics and psychiatric conditions, contributing to its Q3 and Q2 quartile rankings across multiple relevant categories in 2023. The importance of this journal cannot be understated; it serves as a crucial resource for researchers, clinicians, and students eager to uncover insights that could lead to more effective interventions and treatments in the realm of mental health.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.